Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.(600196),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

600196 Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.

Closed 11-12 15:00:00

22.81

-0.11

-0.48%

High22.98	Low22.64	Vol12.64M
Open22.82	D1 Closing22.92	Amplitude1.48%
Mkt Cap60.90B	Tradable Cap48.31B	Total Shares2.67B
T/O288.00M	T/O Rate0.60%	Tradable Shares2.12B
P/B1.21	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"600196","market":"SH","secType":"STK","nameCN":"Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.","latestPrice":22.81,"timestamp":1794466800000,"preClose":22.92,"halted":0,"volume":12642215,"delay":0,"changeRate":-0.0048,"floatShares":2118000000,"shares":2670000000,"eps":1.3162,"marketStatus":"Closed","change":-0.11,"latestTime":"11-12 15:00:00","open":22.82,"high":22.98,"low":22.64,"amount":288000000,"amplitude":0.0148,"askPrice":22.81,"askSize":53,"bidPrice":22.8,"bidSize":151,"shortable":0,"etf":0,"ttmEps":1.3162,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1794533400000},"marketStatusCode":5,"adr":0,"adjPreClose":22.92,"symbolType":"stock","openAndCloseTimeList":[[1794447000000,1794454200000],[1794459600000,1794466800000]],"highLimit":25.21,"lowLimit":20.63,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":2670429325,"isCdr":false,"pbRate":1.21,"roa":"--","peRate":17.330193,"roe":"5.42%","epsLYR":1.27,"committee":0.313243,"marketValue":60912000000,"turnoverRate":0.006,"status":1,"hkstockBrief":{"symbol":"02196","market":"HK","secType":"STK","nameCN":"FOSUN PHARMA","latestPrice":16.57,"timestamp":1794470886003,"preClose":16.73,"halted":0,"volume":2084548,"delay":0,"premium":"-38.20"},"floatMarketCap":48323000000},"requestUrl":"/m/hq/s/600196/wiki","defaultTab":"wiki","newsList":[{"id":"2682627085","title":"Fosun Pharma Unit Begins Trial of Non-Hodgkin Lymphoma Drug in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2682627085","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682627085?lang=en_us&edition=fundamental","pubTime":"2026-11-12 19:11","pubTimestamp":1794481907,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical (Group) (SHA:600196, HKG:2196) unit Fosun Kairos (Shanghai) Biological Technology initiated a phase II clinical trial of FKC516 Injection in Mainland China.The drug is be","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02196","BK0028","BK0183","600196","BK0187","BK1593","BK0239","BK0188","BK1191","BK1515","BK0175","BK0012","BK0060","BK0196","BK0096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154729865","title":"Fosun Pharma's FKC516 Injection Enters Phase II Clinical Trial in China for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=1154729865","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1154729865?lang=en_us&edition=fundamental","pubTime":"2026-11-12 18:12","pubTimestamp":1794478331,"startTime":"0","endTime":"0","summary":"Fosun Pharma (02196) has announced that its controlled subsidiary, Fosun Kairui (Shanghai) Biotechnology Co., Ltd., has launched a Phase II clinical trial in China for FKC516 Injection (FKC516) in...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0012","BK0239","BK0187","BK0060","BK1515","PSYK","BK0196","BK0188","MDTX","600196","BK0096","BK1191","IBBJ","02196","BK0183","BK1593","BMED","BK0175","IBBQ","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682362710","title":"Sinopharm Group Stock Slides 0.6% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2682362710","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682362710?lang=en_us&edition=fundamental","pubTime":"2026-11-10 16:33","pubTimestamp":1794299580,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Sinopharm Group Co. Ltd. slid 0.6% to 17.05 Hong Kong dollars on what proved to be an all-around positive trading session for the Hong Kong stock market, with the Hang Seng Index rising 0.4% to 24557.04.This was the stock's second consecutive day of losses.Sinopharm Group Co. Ltd. closed 24% below its 52-week high of HK$22.34, which the company achieved Feb. 25.The stock underperformed when compared to some of its competitors, as Shanghai Fosun Pharmaceutical  Co. Ltd. rose 1.3%.Trading volume totaled 3.5 million shares, compared to the 50-day average of 5.9 million shares.Data source: Dow Jones Market Data, FactSet","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK0060","BK1197","600196","01099","02196","BK0183","BK1500","BK1515","BK4175","SHTDY","BK1593","BK0096","BK0239","BK0012","LU0640798160.USD","LU1115378108.SGD","BK0187","BK0028","BK0175","BK0188","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681855108","title":"Sinopharm Group Stock Advances 1.1% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2681855108","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681855108?lang=en_us&edition=fundamental","pubTime":"2026-11-06 16:33","pubTimestamp":1793953980,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Sinopharm Group Co. Ltd. advanced 1.1% to 17.16 Hong Kong dollars on what proved to be an all-around dismal trading session for the Hong Kong stock market, with the Hang Seng Index falling 1.3% to 24481.86.This was the stock's second consecutive day of gains.Sinopharm Group Co. Ltd. closed 23% short of its 52-week high of HK$22.34, which the company achieved Feb. 25.The stock outperformed some of its competitors, as Shanghai Fosun Pharmaceutical  Co. Ltd. fell 0.1%.Trading volume totaled 6.1 million shares, compared to the 50-day average of 5.9 million shares.Data source: Dow Jones Market Data, FactSet","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1593","BK1191","BK0060","BK0188","BK0012","01099","BK0187","BK0028","600196","BK0096","BK1500","LU1115378108.SGD","BK0196","BK4175","BK0239","BK0183","02196","BK1515","SHTDY","LU0640798160.USD","BK1197","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681801653","title":"Fosun Pharma Subsidiary Waives Right to Receive Transferred Shares in Biologics-Focused Equity Fund","url":"https://stock-news.laohu8.com/highlight/detail?id=2681801653","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681801653?lang=en_us&edition=fundamental","pubTime":"2026-11-05 11:29","pubTimestamp":1793849353,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical's  subsidiary, Suzhou Junming, agreed to the addition of a new investor in its biologics-focused private equity fund, Hangzhou Fund, and waived its right to receive shares transferred from another investor, according to a Shanghai bourse filing Thursday.Porton Pharma Solutions acquired the 3.75% stake in the fund, which is worth 30 million yuan, from Ningbo Xinhui.After the transaction, Ningbo Xinhui's share in the fund was reduced to 3.13% from 6.88%.The pharmaceutical company's Shanghai and Hong Kong shares both rose 1% during the morning trade.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02196","BK0239","BK0060","BK4215","REZ","BK0196","BK4588","BK0012","BK4585","BK0183","EQR","600196","BK0188","BK1515","BK1593","BK0028","BK0175","BK0187","BK0096","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680032106","title":"Fosun Pharma Unit Begins Trial of FXS6837 Capsules for Gemoglobinuria in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2680032106","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680032106?lang=en_us&edition=fundamental","pubTime":"2026-11-04 18:50","pubTimestamp":1793789439,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical   unit Shanghai Fosun Pharmaceutical Industrial Development began the phase III clinical trial of FXS6837 capsules.The drug is being tested for the treatment of paroxysmal nocturnal hemoglobinuria in the Chinese mainland, a Wednesday bourse filing showed.","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0096","BK0183","BK0187","600196","BK0239","BK0188","BK0012","BK1515","BK0175","BK0060","BK0028","BK0196","BK1593","BK1191","02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179429142","title":"Phase III Clinical Trial of FXS6837 Capsules for Paroxysmal Nocturnal Hemoglobinuria Initiated in China by Fosun Pharma","url":"https://stock-news.laohu8.com/highlight/detail?id=1179429142","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179429142?lang=en_us&edition=fundamental","pubTime":"2026-11-04 17:52","pubTimestamp":1793785936,"startTime":"0","endTime":"0","summary":"Fosun Pharma (02196) has issued an announcement that its controlling subsidiary, Shanghai Fosun Pharmaceutical Industry Development Co., Ltd., has launched a Phase III clinical trial in China for...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0060","BK1593","BK1191","BK0196","MDTX","BK0183","BK0175","BK0012","600196","PSYK","BK1515","BK0187","BK0188","BK0028","BK0239","IBBQ","IBBJ","02196","BK0096","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680039067","title":"Shanghai Fosun Pharma - Subsidiary Initiates Phase Iii Trial of Fxs6837 Capsules for Pnh","url":"https://stock-news.laohu8.com/highlight/detail?id=2680039067","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680039067?lang=en_us&edition=fundamental","pubTime":"2026-11-04 17:48","pubTimestamp":1793785733,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261104:nFWN46L0VV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0239","BK0060","BK0183","BK0028","BK1191","BK1593","600196","BK0175","BK0012","BK0187","BK1515","BK0188","BK0196","BK0096","02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133724447","title":"Fosun Pharma's Subsidiary Gains Approval for HLX109 Injection Clinical Trial in Australia","url":"https://stock-news.laohu8.com/highlight/detail?id=1133724447","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1133724447?lang=en_us&edition=fundamental","pubTime":"2026-11-04 17:12","pubTimestamp":1793783531,"startTime":"0","endTime":"0","summary":"Fosun Pharma (600196.SH) has announced that its controlling subsidiary Shanghai Henlius Biotech, Inc. and its controlled subsidiaries (collectively \"Henlius\") have received approval from the relevant...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","BK0175","BK0012","BK1593","BK0187","IBBJ","BK0028","BK0188","MDTX","600196","BMED","BK1191","BK0060","BK1515","BK0096","BK0196","IBBQ","02196","PSYK","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124334568","title":"Fosun International Climbs Nearly 5% as Subsidiaries Post Strong Results; Fosun Pharma's Nine-Month Adjusted Net Profit Rises Over 8%","url":"https://stock-news.laohu8.com/highlight/detail?id=1124334568","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124334568?lang=en_us&edition=fundamental","pubTime":"2026-11-04 16:24","pubTimestamp":1793780656,"startTime":"0","endTime":"0","summary":"Fosun International (00656) closed nearly 5% higher. The stock ended the day up 4.74% at HK$4.64, with turnover of HK$30.67 million. On the news front, several listed companies under Fosun...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0012","BK0187","BK4585","VXUS","02196","00656","BK0096","BK0196","BK4588","BK1515","KCAI","BK1191","BK1593","BK0175","600196","BK0239","BK0188","BK0060","BK1230","BK0028","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141217693","title":"Two-Year Vacancy Finally Filled: Peng Yulong Officially Takes the Helm at Fosun United Health, New Challenges After 8 Billion Yuan","url":"https://stock-news.laohu8.com/highlight/detail?id=1141217693","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141217693?lang=en_us&edition=fundamental","pubTime":"2026-11-03 20:22","pubTimestamp":1793708563,"startTime":"0","endTime":"0","summary":"The chairman's seat had been empty for two years. In September 2024, Zeng Mingguang resigned. In October 2026, Peng Yulong's qualifications as chairman were approved. During this period, an 810...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0188","02196","BK0028","BK0096","BK0175","BK0196","BK0060","BK0183","BK0239","BK0187","600196","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680574304","title":"Sinopharm Group Stock Rallies 2.4% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2680574304","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680574304?lang=en_us&edition=fundamental","pubTime":"2026-11-03 16:33","pubTimestamp":1793694780,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Sinopharm Group Co. Ltd. rallied 2.4% to 16.73 Hong Kong dollars on what proved to be an all-around great trading session for the Hong Kong stock market, with the Hang Seng Index rising 0.6% to 23525.97.This was the stock's third consecutive day of gains.Sinopharm Group Co. Ltd. closed 25% below its 52-week high of HK$22.34, which the company achieved Feb. 25.The stock outperformed some of its competitors, as Shanghai Fosun Pharmaceutical  Co. Ltd. rose 1.6%.Trading volume totaled 8.1 million shares, compared to the 50-day average of 5.8 million shares.Data source: Dow Jones Market Data, FactSet","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1197","BK0175","BK0188","BK1191","BK0187","BK0028","02196","BK0183","BK0012","BK1515","BK1593","600196","BK1500","BK0196","SHTDY","BK0060","LU0640798160.USD","LU1115378108.SGD","BK0096","01099","BK0239","BK4175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680371717","title":"Shanghai Fosun Pharmaceutical Files HKEX Next-Day Return Disclosing Share Buyback","url":"https://stock-news.laohu8.com/highlight/detail?id=2680371717","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680371717?lang=en_us&edition=fundamental","pubTime":"2026-11-02 17:20","pubTimestamp":1793611206,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical Files HKEX Next-Day Return Disclosing Share BuybackFosun Pharma repurchased 2,000,000 H shares for HKD 33.32 million on November 2, 2026.Repurchase prices ranged from HKD","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261102:nNDL8DZGGW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0196","BK0175","BK0187","BK0096","600196","00656","BK1230","BK0012","BK0028","BK0188","BK0239","BK0183","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153121886","title":"FOSUN PHARMA Spends Approximately HK$5.2536 Million to Buy Back 320,000 Shares on October 30","url":"https://stock-news.laohu8.com/highlight/detail?id=1153121886","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153121886?lang=en_us&edition=fundamental","pubTime":"2026-10-30 18:02","pubTimestamp":1793354535,"startTime":"0","endTime":"0","summary":"FOSUN PHARMA (02196) has announced that on October 30, 2026, the company spent approximately HK$5.2536 million to repurchase 320,000 shares at prices ranging from HK$16.09 to HK$16.5 per share.","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0012","BK0028","BK1515","BK1593","600196","02196","BK0096","BK0183","BK0196","BK0239","BK0175","BK0060","BK0188","BK1191","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186221543","title":"FOSUN PHARMA Spends HK$33.4126 Million to Repurchase 2 Million Shares on October 28","url":"https://stock-news.laohu8.com/highlight/detail?id=1186221543","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186221543?lang=en_us&edition=fundamental","pubTime":"2026-10-28 17:16","pubTimestamp":1793178976,"startTime":"0","endTime":"0","summary":"On October 28, 2026, FOSUN PHARMA (02196) announced that it repurchased 2 million shares for HK$33.4126 million.","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0183","02196","BK0096","BK0012","BK0187","600196","BK0175","BK0060","BK0028","BK1515","BK1191","BK1593","BK0188","BK0196","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678452313","title":"Shanghai Fosun Pharma Discloses Share Buyback in HKEX Next-Day Return","url":"https://stock-news.laohu8.com/highlight/detail?id=2678452313","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678452313?lang=en_us&edition=fundamental","pubTime":"2026-10-28 17:15","pubTimestamp":1793178903,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharma discloses share buyback in HKEX next-day returnShanghai Fosun Pharmaceutical repurchased 2,000,000 H shares on October 28, 2026, for HKD 33.41 million.Repurchase prices ranged fr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261028:nNDL9PJHYd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1230","BK0096","00656","BK0239","BK0196","600196","BK0183","BK0188","BK0012","BK0060","BK0175","BK0028","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678175509","title":"Shanghai Fosun Pharmaceutical Logs Higher Q3 Attributable Profit; Revenue Up","url":"https://stock-news.laohu8.com/highlight/detail?id=2678175509","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678175509?lang=en_us&edition=fundamental","pubTime":"2026-10-27 18:49","pubTimestamp":1793098149,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical  posted 946 million yuan in profit attributable to shareholders of the listed company for the third quarter, up 15% from a year prior.EPS moved 16.13% higher year over year to 0.36 yuan, a Tuesday filing with the Hong Kong Exchange showed.For the three months ended Sept. 30, operating revenue was 10 billion yuan, an increase of 1.4% from the year-ago period, the company said.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0028","BK1515","BK0096","BK0183","BK0175","BK1593","BK0239","02196","BK0060","BK0196","BK0187","600196","BK0012","FCA","BK0188","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678121391","title":"Sinopharm Group Stock Advances 2.3% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2678121391","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678121391?lang=en_us&edition=fundamental","pubTime":"2026-10-27 16:32","pubTimestamp":1793089920,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Sinopharm Group Co. Ltd. rose 2.3% to 16.30 Hong Kong dollars on what proved to be an all-around rough trading session for the Hong Kong stock market, with the Hang Seng Index falling 0.7% to 23041.32.This was the stock's second consecutive day of gains.Sinopharm Group Co. Ltd. closed 27% below its 52-week high of HK$22.34, which the company achieved Feb. 25.The stock outperformed some of its competitors, as Shanghai Fosun Pharmaceutical  Co. Ltd. fell 1.4%.Trading volume totaled 8.8 million shares, compared to the 50-day average of 5.5 million shares.Data source: Dow Jones Market Data, FactSet","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1197","BK0175","LU0640798160.USD","LU1115378108.SGD","SHTDY","BK0012","BK0188","600196","BK1191","BK0187","BK0183","02196","BK1593","BK0060","BK0239","BK0196","BK0096","BK0028","BK1515","BK1500","BK4175","01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678129779","title":"Shanghai Fosun Pharmaceutical Group Q3 Net Profit up 15.2% Y/Y","url":"https://stock-news.laohu8.com/highlight/detail?id=2678129779","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678129779?lang=en_us&edition=fundamental","pubTime":"2026-10-27 16:29","pubTimestamp":1793089744,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261027:nL3N46D0ML:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0028","BK0239","BK0183","BK0096","BK0175","BK0196","BK0188","600196","BK0187","BK0060","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678168212","title":"Sinopharm Group Stock Rises 3.8% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2678168212","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678168212?lang=en_us&edition=fundamental","pubTime":"2026-10-26 16:31","pubTimestamp":1793003460,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Sinopharm Group Co. Ltd. advanced 3.8% to 15.93 Hong Kong dollars on what proved to be an all-around favorable trading session for the Hong Kong stock market, with the Hang Seng Index rising 0.5% to 23211.81.The stock's rise snapped a two-day losing streak.Sinopharm Group Co. Ltd. closed 29% below its 52-week high of HK$22.34, which the company reached Feb. 25.The stock outperformed some of its competitors, as Shanghai Fosun Pharmaceutical  Co. Ltd. rose 1.0%.Trading volume totaled 11.6 million shares, compared to the 50-day average of 5.4 million shares.Data source: Dow Jones Market Data, FactSet","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0188","BK4175","SHTDY","BK0239","BK0028","LU0640798160.USD","BK0183","BK1197","BK1515","LU1115378108.SGD","BK1593","02196","BK1191","BK0187","BK0012","BK0060","01099","BK0175","BK1500","600196","BK0196","BK0096"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1794521797874,"stockEarnings":[{"period":"1week","weight":-0.0359},{"period":"1month","weight":-0.0298},{"period":"3month","weight":-0.0578},{"period":"6month","weight":-0.0384},{"period":"1year","weight":-0.1847},{"period":"ytd","weight":-0.124}],"compareEarnings":[{"period":"1week","weight":-0.0092},{"period":"1month","weight":-0.0382},{"period":"3month","weight":-0.0691},{"period":"6month","weight":-0.116},{"period":"1year","weight":-0.0861},{"period":"ytd","weight":-0.0789}],"compareStock":{"symbol":"000001.SH","name":"SSE Comp"},"companyName":"上海复星医药(集团)股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"0人","perCapita":"--","listingDate":"1998-08-07","address":"上海市普陀区曹杨路510号9楼","registeredCapital":"267042万元","survey":"　　上海复星医药(集团)股份有限公司的主营业务是制药、医疗器械与医学诊断、医疗健康服务，并通过参股国药控股覆盖到医药商业领域。公司的主要产品是注射用曲妥珠单抗（中国境内商品名：汉曲优）及曲妥珠单抗原液、汉利康（利妥昔单抗注射液）、斯鲁利单抗注射液（中国境内商品名：汉斯状）、奥康泽(奈妥匹坦帕洛诺司琼胶囊)、奕凯达（阿基仑赛注射液）、一心坦（沙库巴曲缬沙坦钠片）、汉贝泰（贝伐珠单抗注射液）、汉奈佳（马来酸奈拉替尼片）、倍稳（盐酸凯普拉生片）、珮金（拓培非格司亭注射液）、苏可欣（马来酸阿伐曲泊帕片）、汉达远（阿达木单抗注射液）、普瑞尼（普托马尼片）、达希斐（注射用A型肉毒毒素）、复可舒（抗人T细胞兔免疫球蛋白）、复迈宁（芦沃美替尼片）、欧泰乐（阿普米司特片）、地舒单抗注射液、复妥宁（枸橼酸伏维西利胶囊）、汉倍优（帕妥珠单抗注射液）、万缇乐（盐酸替那帕诺片）、旁必福（盐酸依特卡肽注射液）。","listedPrice":7.15},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.(600196),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.(600196) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.,600196,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票老虎,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票老虎国际,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.行情,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票行情,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股价,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股市,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票价格,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票交易,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票购买,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.(600196),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.(600196) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction